 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Angelo D'Alessandro and Austin Gillen.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.455 |
|
|
|
-
Amaya ML, Abbott D, McMahon CM, Schwartz MS, Gutman JA, Kent A, Angelos MG, Sohalski C, Belachew A, Dell-Martin J, Anttila K, Stevens BM, D'Alessandro A, Showers WM, Gillen AE, Jordan CT, Pollyea DA. A Phase 1/1b Study of the All-Oral Regimen CC-486 and Venetoclax in Acute Myeloid Leukemia. Blood Adv. 2026 Jul 24.
Score: 0.062
-
Patel SB, Moskop DR, Moreira S, Gipson S, Anderson CC, Crook A, McCabe M, Stephenson D, Terry HE, Kent A, Young TN, Krug AE, Thomas CI, Price C, Ransom M, Miller R, Vujovic A, Minhajuddin M, Althoff MJ, Consortium TC, Saviola AJ, Stevens BM, Welner RS, Andrianova EL, Gudkov AV, Darehshouri A, Reisz JA, Nemkov T, D'Alessandro A, Gillen AE, Pollyea DA, Jordan CT, Pietras EM. The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells. Blood Cancer Discov. 2026 Jul 21.
Score: 0.062
-
Gil KB, Borg J, Pereira RM, Inguva-Sheth A, Araujo G, Rahkola J, Showers W, Grier A, D'Alessandro A, Smith C, McMahon C, Pollyea DA, Gillen AE, Amaya ML. The STAT3-VDAC1 axis modulates mitochondrial function and plays a critical role in the survival of acute myeloid leukemia cells. Haematologica. 2026 Feb 01; 111(2):481-492.
Score: 0.058
-
Althoff MJ, Minhajuddin M, Stevens BM, Gillen AE, Gipson S, Patel SB, Shelton IT, Miller R, Vujovic A, Krug A, Young T, Showers WM, Dzieciatkowska M, Stephenson D, Tyagi A, Ellegast JM, Wright T, Stegmaier K, Opferman JT, D'Alessandro A, Smith CA, Jordan CT. Therapy resistance in AML is mediated by cytoplasmic sequestration of the transcriptional repressor IRF2BP2. bioRxiv. 2025 May 24.
Score: 0.057
-
Minhajuddin M, Winters A, Ye H, Pei S, Stevens B, Gillen A, Engel K, Gipson S, Ransom M, Amaya M, Inguva A, Gasparetto M, Althoff MJ, Miller R, Shelton I, Tolison H, Krug A, Culp-Hill R, D'Alessandro A, Sherbenou DW, Pollyea DA, Smith C, Jordan CT. Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia. Haematologica. 2025 Jan 01; 110(1):103-116.
Score: 0.056
-
Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D'Alessandro A, Winters A, Krug A, Abbott D, Goosman M, Pei S, Ye H, Gillen AE, Becker MW, Savona MR, Smith C, Jordan CT. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020 12; 1(12):1176-1187.
Score: 0.042
-
Burchill MA, Finlon JM, Goldberg AR, Gillen AE, Dahms PA, McMahan RH, Tye A, Winter AB, Reisz JA, Bohrnsen E, Schafer JB, D'Alessandro A, Orlicky DJ, Kriss MS, Rosen HR, McCullough RL, Jirón Tamburini BA. Oxidized Low-Density Lipoprotein Drives Dysfunction of the Liver Lymphatic System. Cell Mol Gastroenterol Hepatol. 2021; 11(2):573-595.
Score: 0.042
-
Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D'Alessandro A, Gutman JA, Ramsey HE, Savona MR, Smith CA, Jordan CT. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov. 2020 04; 10(4):536-551.
Score: 0.040
-
Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselberth JR, Abbott D, Schatz D, Gutman JA, Purev E, Smith C, Jordan CT. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018 12; 24(12):1859-1866.
Score: 0.037
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|